---
layout: default
title: Lanreotide
parent: Model Prediction Only (L5)
nav_order: 442
evidence_level: L5
indication_count: 5
---

# Lanreotide
{: .fs-9 }

Evidence Level: **L5** | Predicted Indications: **5** 
{: .fs-6 .fw-300 }

---

## Table of Contents
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## Pharmacist Assessment Report

</div>

# Lanreotide: Original Indication Not Captured — Predicted New Indication: Hypertrichosis (Disease)

## One-Sentence Summary

Lanreotide (DrugBank DB06791) is a somatostatin analog; this evidence pack does not contain its approved original indication or a structured mechanism-of-action record. The TxGNN model assigns a very high score (99.97%) to a potential link with **Hypertrichosis (disease)**, but this candidate is currently supported by **zero clinical trials** and **zero relevant publications**, making it an unverified, model-only signal.

---

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Not available — no Canadian marketing licenses and no original indication text in this evidence pack |
| Predicted New Indication | Hypertrichosis (disease) |
| TxGNN Prediction Score | 99.97% (rank 1054) |
| Evidence Level | L5 — model prediction only, no supporting studies |
| Canada Market Status | ✗ Not Marketed |
| Number of DINs | 0 |
| Recommended Decision | Hold |

---

## Why is This Prediction Reasonable?

Detailed mechanism-of-action data for lanreotide is flagged as a data gap in this evidence pack (DG002, High severity). Based on the repurposing rationale accompanying the prediction, lanreotide is known to act as a **somatostatin analog**, binding SSTR2/SSTR5 receptors to suppress growth hormone, IGF-1, and various gastroenteropancreatic hormone secretion — this is consistent with its established clinical class, though the original approved indication itself is not recorded in this pack.

No pharmacological pathway connects somatostatin receptor agonism to hair follicle growth regulation, and the evidence pack's own rationale states the high TxGNN score is likely driven by **knowledge-graph node proximity rather than a genuine mechanistic relationship**. No clinical trials, ICTRP records, or PubMed literature specific to lanreotide and hypertrichosis were found in any of the three source queries.

The same evidence pack also screened four additional top-ranked candidates (periodontal/odontal malformation syndrome, Dandy-Walker malformation syndrome, isolated genetic hair shaft abnormality, and Ambras-type congenital hypertrichosis universalis). All received the same L5/Hold classification. Notably, 20 PubMed articles matched the "periodontal malformation" candidate on keyword overlap, but manual title review found none actually discuss lanreotide or somatostatin analogs — a likely false-positive text-matching artifact rather than real evidence.

---

## Clinical Trial Evidence

Currently no related clinical trials registered.

---

## Literature Evidence

Currently no related literature available.

---

## Canada Market Information

This drug currently has no marketing authorization (DIN) in Canada — `taiwan_regulatory.market_status` is "Not marketed" (Not Marketed) with 0 total licenses on record.

---

## Safety Considerations

Please refer to the package insert for safety information.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The top-ranked candidate indication (Hypertrichosis) has no clinical trial, ICTRP, or literature support, and the pack's own rationale attributes the TxGNN score to knowledge-graph proximity rather than a plausible mechanism. Combined with the drug's unmarketed status in Canada and missing MOA/original-indication data, this candidate does not meet the bar to advance past S0.

**To proceed, the following is needed:**
- Confirmed original approved indication(s) and structured MOA data via DrugBank API (DG002)
- TFDA/Health Canada label warnings and contraindications (DG001 — currently blocking safety review)
- A genuine mechanistic hypothesis linking somatostatin receptor signaling to the candidate indication, reviewed by a clinical pharmacologist
- Preclinical or case-level evidence before considering progression beyond S0/Hold
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

